<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialSourcesOutput xmlns:ns2="local"><Sources><Source id="1297822" type="PR">Debiopharm Presented Results at the ASCO 2012 Annual Meeting - Results of Phase I Study With Debio 0932, an Oral HSP90 Inhibitor in Patients With Solid Tumours</Source><Source id="1263604" type="PR">Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of HSP90 Inhibitor Debio 0932</Source><Source id="1096515" type="PR">Curis Reports First Quarter 2010 Financial Results</Source><Source id="1094357" type="PR">Curis Licensee Debiopharm Initiates Phase I Clinical Trial of Hsp90 Inhibitor Debio 0932</Source><Source id="1094142" type="PR">Debiopharm Group(TM) Starts Phase I Clinical Trial With Debio 0932</Source><Source id="1077452" type="PR">Curis Reports Fourth Quarter and Year-End 2009 Financial Results</Source><Source id="1074961" type="PR">Curis Achieves Milestone Under Hsp90 Collaboration with Debiopharm</Source><Source id="1663190" type="SERIAL">Debio0932, a second-generation oral heat shock protein (hsp) inhibitor, in patients with advanced cancer-results of a first-in-man dose-escalation study with a fixed-dose extension phase</Source><Source id="1562096" type="OTHER">Final results from the phase I study expansion cohort of Debio0932, an oral HSP90 inhibitor, in patients with solid tumors</Source><Source id="1299493" type="OTHER">A phase I study of Debio 0932, an oral HSP90 inhibitor, in patients with solid tumors</Source></Sources></ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialSourcesOutput>